GhayasC.IssaMD

PubMed

• Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
  Wei-Ying Jen, Farhad Ravandi, Hagop Kantarjian, Tapan M Kadia, Courtney D DiNardo, Ghayas C Issa, Nicholas J Short, Musa Yilmaz, Gautam Borthakur, Naval G Daver> ;British Journal of Haematology. 2024 May 9
• Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
  Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, Tapan Kadia, Naval Daver, Courtney D DiNardo, Gautam Borthakur, Sanam Loghavi, Keyur Patel, Guilin Tang, Koji Sasak...> ;Haematologica. 2024 May 2
• Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing ...
  Lewis F Nasr, Jayastu Senapati, Rebecca Garris, Farhad Ravandi, Nicholas J Short, Elias Jabbour, Nitin Jain, Fadi G Haddad, Ghayas C Issa, Koji Sasaki, Partow Kebriaei...> ;American Journal of Hematology. 2024 Apr 12
• Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
  Wei-Ying Jen, Wei Qiao, Farhad Ravandi, Koji Sasaki, Sanam Loghavi, Sa A Wang, Gautam Borthakur, Tapan M Kadia, Ghayas C Issa, Nicholas J Short, Musa Yilmaz, Naval G D...> ;British Journal of Haematology. 2024 Apr 11
• Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
  Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
• Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
  Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
• 1 citations
  Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
  Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
• The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in ...
  Fadi G Haddad, Koji Sasaki, Ghayas C Issa, Elias Jabbour, Hagop Kantarjian> ;American Journal of Hematology. 2024 Mar 28
• Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma.
  Fnu Sameeta, Hong Fang, Wei Wang, Zhenya Tang, Sa A Wang, Gokce A Toruner, Xenia Parisi, Joseph D Khoury, Ghayas Issa, Guillermo Garcia-Manero, L Jeffrey Medeiros, Gui...> ;American Journal of Hematology. 2024 Mar 5
• Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
  Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti...> ;The Lancet. Haematology. 2024 Apr 1
• Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib.
  Cedric Nasnas, Shilpa Paul, Caitlin Rausch, Fadi G Haddad, Koji Sasaki, Ghayas C Issa, Elias Jabbour, Hagop Kantarjian> ;Clinical Lymphoma, Myeloma &amp; Leukemia. 2024 Feb 29
• Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
  Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, Rashmi Kanagal-Shamanna, Danielle Hammond, Kelly Chien, Koji Sasaki, Elias Jabbour, Cour...> ;Leukemia. 2024 May 1
• 1 citations
  Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
  Dinh, A., Savoy, J., Rausch, C., Kontoyiannis, D., Takahashi, K., Issa, G., Kantarjian, H., DiNardo, C.> ;Cancer. 2024 Feb 10
• 2 citations
  Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2...
  Bataller, A., Montalban-Bravo, G., Bazinet, A., Alvarado, Y., Chien, K., Venugopal, S., Ishizawa, J., Hammond, D., Swaminathan, M., Sasaki, K., Issa, G., Short, N., Ma...> ;The Lancet. Haematology. 2024 Mar 1
• 1 citations
  Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory-Mutated AML.
  Nicholas J Short, Naval Daver, Courtney D Dinardo, Tapan Kadia, Lewis F Nasr, Walid Macaron, Musa Yilmaz, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia...> ;Journal of Clinical Oncology. 2024 May 1
• 2 citations
  Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
  Alex Bataller, Alexandre Bazinet, Courtney D DiNardo, Abhishek Maiti, Gautam Borthakur, Naval G Daver, Nicholas J Short, Elias J Jabbour, Ghayas C Issa, Naveen Pemmara...> ;Blood Advances. 2024 Feb 27
• 2 citations
  Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, an...
  Koji Sasaki, Fadi G Haddad, Nicholas J Short, Nitin Jain, Ghayas Issa, Elias Jabbour, Hagop Kantarjian> ;Cancer. 2023 Dec 1
• 2 citations
  Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
  Danielle Hammond, Sanam Loghavi, Sa A Wang, Marina Y Konopleva, Tapan M Kadia, Naval G Daver, Maro Ohanian, Ghayas C Issa, Yesid Alvarado, Nicholas J Short, Koji Sasak...> ;Blood Cancer Journal. 2023 Sep 21
• 7 citations
  Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
  Alex Bataller, Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S Chien, Danielle Hammond, Guillermo Montalban-Bravo, Gautam Borthakur, Nicholas ...> ;American Journal of Hematology. 2023 Nov 1
• Myeloid lineage switch inrearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies.
  Alex Bataller, Tareq Abuasab, David McCall, Wei Wang, Branko Cuglievan, Ghayas C Issa, Elias Jabbour, Nicholas Short, Courtney D DiNardo, Guilin Tang, Guillermo Garcia...> ;Haematologica. 2024 Jan 1
• Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
  Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, Danielle Hammond, Kelly Chien, Juan Jose Rodriguez-Sevilla, Koji Sasaki, Elias Jabbour, Courtney DiNardo, ...> ;British Journal of Haematology. 2023 Nov 1
• 2 citations
  Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
  Jayastu Senapati, Warren C Fiskus, Naval Daver, Nathaniel R Wilson, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Courtney D DiNardo, Elias Jabbour, Jan Burger...> ;Clinical Cancer Research. 2023 Nov 1
• 1 citations
  Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.
  Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William Wierda, Naval Daver, ...> ;Clinical Lymphoma, Myeloma &amp; Leukemia. 2023 Nov 1
• 1 citations
  Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
  Fadi G Haddad, Koji Sasaki, Aram Bidikian, Ghayas C Issa, Tapan Kadia, Nitin Jain, Yesid Alvarado, Nicholas J Short, Naveen Pemmaraju, Sanam Loghavi, Keyur P Patel, Ra...> ;American Journal of Hematology. 2023 Oct 1
• 16 citations
  Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
  Jayastu Senapati, Samuel Urrutia, Sanam Loghavi, Nicholas J Short, Ghayas C Issa, Abhishek Maiti, Hussein A Abbas, Naval G Daver, Naveen Pemmaraju, Sherry Pierce, Kell...> ;Blood. 2023 Nov 9
• Join now to see all

Abstracts/Posters

• Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Periphera...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute ...
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
  Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018